Lilly Commits $4.5 B to Indiana Expansion; Amazon Launches Oral Ozempic Pill
Eli Lilly will allocate an additional $4.5 billion toward its Indiana facilities to expand biomanufacturing capacity for insulin and GLP-1 therapies. Amazon’s planned launch of an oral Ozempic GLP-1 pill intensifies competition in the diabetes and weight-loss market against Lilly’s injectable products.
1. Indiana Biomanufacturing Expansion
Eli Lilly is investing $4.5 billion into its Indiana campus to increase biomanufacturing capacity for insulin and GLP-1 therapies, aiming to meet rising global demand. The funds will support facility upgrades, process automation and workforce expansion over the next several years.
2. Oral GLP-1 Pill Competition
Amazon’s introduction of an oral Ozempic GLP-1 pill marks its entry into the diabetes and weight-loss sector, potentially exerting pricing pressure on injectable GLP-1 products. This move could reshape distribution channels and intensify market share battles for Lilly’s established injectable therapies.